RBD-5044

N/A

Report date: 2026/05/15 20:01:45
NME

Base Information

Drug NameRBD-5044
Drug Alias NameRBD-5044SR044SR-044GalNAc 偶联的 siRNA RBD-5044GalNAc-conjugated siRNA RBD-5044
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Oligonucleotide > Small Interfering RNA
Mechanisms of ActionApolipoprotein C-III inhibitors
TargetsApolipoprotein C-III
Therapy Area/IndicationsHypertriglyceridemiaHyperlipidemiasDyslipidemias
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritorySwedenAustraliaMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesSuzhou Ribo Life Science Co Ltd
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesRibotek Biopharmaceuticals (Shandong) Co LtdRibocure Pharmaceuticals ABSuzhou Ribo Life Science Co Ltd
Inactive CompaniesN/A
Active IndicationsHypertriglyceridemiaHyperlipidemiasDyslipidemias
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A